Initiated 2026-10-19 · Price $184.53 (as of 2026-10-19 intraday, stockanalysis.com; $185.10 close 2026-10-16) · Mkt cap $11.1bn (59.91mm diluted shares) · Health care / acute-care hospitals and behavioral health facilities · Model: verified

Rating: Hold — Conviction: Low

UHS is cheap on current earnings (~8x forward P/E, ~6.4x model-basis EV/EBITDA), but the discount is mostly earned: the company itself expects its net benefit from Medicaid supplemental programs to fall by ~$500mm a year by 2032 under the One Big Beautiful Bill Act, against ~$2.6bn of EBITDA. With that cut partly absorbed, the base case is worth only a little more than today's price. The bear case sits much further below than the bull case sits above, so there is no edge strong enough for a Buy.

Conviction tests (3a-v-c): T1 fail (Base −5.9% at +1pp reads Hold; +26.5% at −1pp reads Buy, so Hold → Buy at −1pp) · T2 pass (Gordon alone +7.7%, exit-multiple alone +8.6%; Hold on both) · T3 pass (one est. input, the ~$835mm Talkspace debt, worth ~$14/sh or ~7% of Base) · T4 pass (no pending deal, ruling or single-contract event worth >25%; OBBBA is law and sits inside the cases)

Model value range vs price
Bear $86.53Base $199.61Bull $314.85Price $184.53

Business overview

UHS runs two segments: acute-care hospitals with freestanding EDs and ambulatory sites, and behavioral-health facilities in the US and UK. Talkspace (virtual therapy) closed on 2026-08-17 for an ~$835mm enterprise value. FY2025 revenue was $17.36bn (+9.7%) and income from operations $1.99bn. Same-facility acute care alone was $4.98bn of H1 2026's $9.13bn revenue (~55%); behavioral health is most of the rest. Exact facility counts and market mix: n/a (unverified this session). Three variables drive earnings: same-facility volume and pricing (Q2 2026 acute +8.2%, behavioral +7.4%); Medicaid supplemental and state directed payments (DPPs), which swing quarters by $50–100mm; and wages, which were 46.6% of FY2025 revenue.

Competition

In acute care, UHS competes market by market with HCA, Tenet and nonprofit systems. HCA's Q2 2026 same-facility equivalent admissions grew 2.7% against UHS's 2.9% adjusted admissions, so UHS is holding share. HCA, though, took a ~$400mm Q2 pre-tax hit as patients who lost exchange coverage showed up uninsured, a mix risk that applies to UHS too. In behavioral health, Acadia is the main listed rival. Its Q2 same-facility patient days rose 0.8% and revenue was flat (+3.2% excluding Florida and Tennessee supplemental-payment timing), against UHS behavioral revenue +7.4% (Q2 2026 releases). Pressure would show up first in payer mix and supplemental-payment revenue, not in price. Tenet, the closest listed comparable, trades at 6.7x aggregator EV/EBITDA against UHS's 5.9x (stockanalysis.com, 2026-10-19).

Bull case

  1. Volume and pricing hold up — capacity additions keep acute adjusted admissions near +3%, and behavioral revenue per admission keeps rising 5–7%. Revenue grows 5.5–6.5% into 2028 and margin holds near 14.8%. Plays out if same-facility revenue stays above +6% through 2027. Model: rev_growth, ebitda_margin
  2. The OBBBA cut is mitigated — states restructure provider-tax and directed-payment programs, and cost discipline offsets most of the ~$500mm, so margin is still 14.5% in 2030. Plays out if 2027–28 state plan approvals keep DPP revenue near current levels. Model: ebitda_margin
  3. Policy clarity re-rates the stock — once the phase-down is known and absorbed, the exit multiple moves to 8.0x (between THC and HCA), WACC falls to 7.8% and terminal growth rises to 2.5%. Model: wacc, terminal_growth, exit_ev_ebitda

Bear case

  1. Supplemental payments are cut in full — the ~$500mm net-benefit reduction (company estimate, Aug 2026 prospectus) lands roughly pro rata from state fiscal 2028 with no offset. Plays out if states cannot replace provider-tax funding. Model: ebitda_margin
  2. Payer mix deteriorates — Medicaid work requirements and lost exchange coverage push patients into uninsured, and behavioral volume (Q2 adjusted admissions +0.5%) stays flat. Revenue grows 2.5–3% after 2026 and margin falls to 12.0% by 2030, near FY2023's 12.2%. Plays out if uninsured admissions rise in UHS's Q3/Q4 data as they did at HCA. Model: rev_growth, ebitda_margin
  3. Permanent policy discount — reimbursement risk keeps the stock cheap: 9.3% WACC, 1% terminal growth, a 5.5x exit. Model: wacc, terminal_growth, exit_ev_ebitda
  4. Capital intensity — capex stays at 6% of revenue and DPP receivables keep NWC at 6% (June 2026: ~5.9%), absorbing cash. Model: capex_pct_rev, nwc_pct_rev

Valuation & balance sheet

Metric (definition) Current Own history (range or 5y avg) Peers Source, as-of
EV/EBITDA, model basis (EV $16.7bn = mkt cap $11.06bn − cash $0.14bn + debt $4.85bn + Talkspace funding $0.84bn est. + NCI $0.14bn; EBITDA after rent) 6.41x FY2025; ~6.1x 2026E 7.39x / 9.60x on FY2024 / FY2023 EBITDA at today's EV THC 6.7x · CYH 7.8x · HCA 9.5x · ACHC 9.7x (aggregator TTM; UHS 5.9x on that basis) model-inputs.json; stockanalysis.com 2026-10-19
P/E 8.1x forward (consensus); ~8.0x on the $22.28–23.65 2026 adjusted guide 18.0x / 11.0x / 8.0x at today's price on GAAP EPS of $10.23 / $16.82 / $23.10 (FY2023–25) THC 13.0x · HCA 15.0x · ACHC 17.8x (forward; CYH n/a) stockanalysis.com 2026-10-19; FY2025 10-K; Q2 release
FCF yield (aggregator TTM) 7.8% 7.7% on FY2025 OCF − capex ($849mm) at today's mkt cap THC 14.1% · HCA 6.0% · ACHC −4.8% · CYH −47.4% stockanalysis.com 2026-10-19; FY2025 10-K

Model-implied value range (from model-summary.json; generic module, Gordon-growth DCF and exit-EV/EBITDA DCF, midpoints): Bear $86.53 · Base $199.61 · Bull $314.85 per share, i.e. implied returns of −53.1% / +8.2% / +70.6% vs $184.53. These ranges show how the bull and bear drivers translate into value; they are not price targets.

Balance sheet: net leverage 2.1x model-basis FY2025 EBITDA, including the estimated Talkspace debt (company-defined debt/adjusted EBITDA net of NCI 1.81x at June 2026, before Talkspace). Coverage 9.6x. Liquidity: $1.27bn undrawn revolver at June 2026, plus a $700mm 364-day delayed-draw term loan. Nearest material maturity: the $700mm 1.650% notes due 2026-09-01, refinanced in August with $600mm 5.500% 2031 and $500mm 6.000% 2036 secured notes. Ratings: n/a (unverified); the prospectus expected investment-grade ratings from Moody's and S&P on the new notes.

Model note: tier full, status built, verification verified (3,207 formula cells matched in LibreOffice). One unverified input: the Talkspace acquisition debt, set at the $835mm deal enterprise value until the Q3 10-Q reports actual borrowings. No assumptions without a basis. Scenario consistency is OK on all 14 rows.

Relative value vs peers
MetricUHSHCATHCCYHACHCPeer medianvs median
P/E (TTM)7.5x15.4x10.5xn/an/a12.9x−42%
P/E (forward)8.1x15.0x12.9xn/a17.8x15.0x−46%
PEG1.1x1.6x1.0xn/an/a1.3x−13%
EV/EBITDA (TTM)5.9x9.5x6.7x7.8x9.7x8.7x−32%
EV/Sales (TTM)0.9x1.9x1.5x0.9x1.6x1.5x−41%
P/B1.4xn/a4.6xn/a1.4x3.0x−52%
FCF yield7.8%6.0%14.1%-47.4%-4.8%0.6%+7.1pp
P/E (TTM)HCA15.4xTHC10.5xUHS7.5x
P/E (forward)ACHC17.8xHCA15.0xTHC12.9xUHS8.1x
PEGHCA1.6xUHS1.1xTHC1.0x
EV/EBITDA (TTM)ACHC9.7xHCA9.5xCYH7.8xTHC6.7xUHS5.9x
EV/Sales (TTM)HCA1.9xACHC1.6xTHC1.5xUHS0.9xCYH0.9x
P/BTHC4.6xUHS1.4xACHC1.4x
FCF yieldTHC14.1%UHS7.8%HCA6.0%ACHC-4.8%CYH-47.4%

As of 2026-10-19. One source and one definition for every company: aggregator TTM and consensus-forward multiples, EV netting all reported cash. Not the model's own EV basis (see the report's valuation table). Quotes taken 2026-10-19 between 09:47 and 10:03 ET with the market open. Dashed line = peer median. Source: stockanalysis.com /stocks/<ticker>/statistics/, fetched 2026-10-19.

Notes. PEG as given by the source, resting on its consensus growth estimates; n/a at the source for CYH and ACHC. CYH's 1.56x TTM P/E is distorted by non-operating gains on a $390mm equity value and is left null; ACHC shows n/a (TTM loss). n/a at the source for CYH. n/a at the source for HCA and CYH (negative or near-zero common equity). UHS's 5.94x uses the source's EBITDA ($2.70bn TTM); on the model's basis (EBITDA after rent, Talkspace funding added to debt, NCI at book) it is 6.41x FY2025.

Scenario stress test

Reasoned from the bull/bear drivers above. The model column comes from the scenario overlays (Base case + shock).

Scenario Effect Mechanism Magnitude Model Δ value vs Base ($/sh)
S1 Fast equity crash − Liquidity de-rating of a beta-1 mid-cap; patient volumes unaffected Med −$13.02
S2 Slow bear / recession − Job losses move commercial patients to Medicaid and uninsured, elective volume falls, bad debt rises. Milder than the bear case, which is a permanent policy cut, not a cycle High −$34.26
S3 Rapid rate shock − Higher discount rate on a ~34%-debt capital structure; pricier refinancing High −$27.93
S4 Slow rate grind − Grinding discount-rate drag Med −$13.73
S5 Soft-landing cuts + Lower rates re-rate the equity; commercial mix intact High +$27.24
S6 Recession-driven cuts − Rate relief outweighed by payer-mix deterioration Low −$5.18
S7a Credit liquidity shock − Spreads gap; ~1.8x-levered secured issuer sold modestly Med −$8.68
S7b Slow default cycle − Pricier refinancing; higher bad debt as households default Med −$10.35
S8 Stagflation − Wages ~46% of revenue while government rates reset with a lag; higher rates Med −$18.89
S9a Dollar spike 0 no material effect, not modeled Low $0.00
S9b Dollar slide 0 no material effect, not modeled Low $0.00
S10 Melt-up − Momentum leadership leaves low-multiple hospitals behind Low −$4.34
S11 Energy supply shock − Utility, supply and second-round wage costs Low −$0.44
S12 Mega-cap/AI derating + Rotation into domestic, non-AI defensives Med +$8.68

Currently active/on watch per the playbook: S3 partially active (price-level leg only); S8, S10 and S11 on watch.

Model value change vs Base, by scenario
S2 Slow bear / recession−$34.26S3 Rapid rate shock−$27.93S8 Stagflation−$18.89S4 Slow rate grind−$13.73S1 Fast equity crash−$13.02S7b Slow default cycle−$10.35S7a Credit liquidity shock−$8.68S6 Recession-driven cuts−$5.18S10 Melt-up−$4.34S11 Energy supply shock−$0.44S9a Dollar spike$0.00S9b Dollar slide$0.00S12 Mega-cap/AI derating+$8.68S5 Soft-landing cuts+$27.24

What would change the call

Upgrades if: management quantifies OBBBA mitigation (state program redesigns, CMS approval of the larger Florida DPP beyond 2025-09-30) that keeps the 2027 margin near 14.5%, while same-facility revenue stays above +6%; or the price falls toward the bear case without new evidence. Downgrades if: Q3/Q4 data show HCA-style uninsured mix shift, 2027 guidance implies margin below 14%, or behavioral volume turns negative.

Watch items

Sources